Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 2104 • ACR Convergence 2023
Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², yoshifumi Ohashi², Shuji Asai² and Shiro Imagama², ¹Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a causative factor in frailty. Large joint symptoms in RA patients may be more strongly associated with physical disability than…
Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Misaki Yoshida¹, takeshi Zoshima², Ichiro Mizushima² and Mitsuhiro Kawano², ¹Kanazawa University, Fukui, Japan, ²Kanazawa University, Kanazawa, Japan
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…
Abstract Number: 2136 • ACR Convergence 2023
Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice
Janine Rupp¹, Johannes Fessler², Silvia Hayer³, Barbara Dreo⁴, Angelika Lackner², Patrizia Fasching², Wolfgang Helmberg², Peter Schlenke², Jens Thiel⁵, Guenter Steiner⁶, Cornelia M. Weyand⁷ and Martin Stradner², ¹Medical University Graz, Rochester, MN, ²Medical University of Graz, Graz, Austria, ³Medical University of VIenna, Vienna, Austria, ⁴Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: T cells play an important role in the genesis of rheumatoid arthritis (RA). HLA class II genes, such as HLA-DRB1*0401 (HLA-DR4), confer the strongest…
Abstract Number: 2152 • ACR Convergence 2023
Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study
Xinjia Deng¹, Yuqing Zhang², Yilun Wang¹, Na Lu³, Dongxing Xie⁴, Houchen Lyu⁵, Jie Wei⁶, Chao Zeng¹, Guanghua Lei¹ and Hui Li¹, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Xiangya Hospital, Central South University, Changsha, China, ⁵Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, ⁶Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and mortality. Many patients with RA underwent knee and…
Abstract Number: 2169 • ACR Convergence 2023
Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Joanna Kedra¹, Benjamin Granger², Lina El Houari³, Florence Tubach⁴ and Bruno Fautrel⁵, ¹Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ⁵Sorbonne Université APHP, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 2438 • ACR Convergence 2023
Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
Órla Tynan¹, Mary Canavan², Achilleas Floudas³, Conor Smith⁴, Aoife O' Rourke⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ³Dublin City University, Dublin, Ireland, ⁴Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Synovial fibroblasts (FLS) are key contributors to joint inflammation and damage in patients with Rheumatoid (RA) and Psoriatic Arthritis (PsA). Recent studies have identified…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: PP10 • ACR Convergence 2023
Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue
Shelley Fritz, Global Healthy Living Foundation, Nyack, NY
Background/Purpose: After my RA diagnosis over eleven years ago, I was optimistic that the first biologic DMARD I took would slow the progression of my…
Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…
Abstract Number: 0385 • ACR Convergence 2023
Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort
Laura BRICMAN¹, clement triaille², Francesco Natalucci³, Emilie Sapart², Tatiana Sokolova⁴, Aleksandra AVRAMOVSKA¹, Thomas KIRCHGESNER⁵ and Patrick Durez², ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³UCLouvain University, Sermoneta, Italy, ⁴Université Catholique de Louvain, Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc Département d'imagerie médicale – Université catholique de Louvain (UCLouvain), Brussels, Belgium
Background/Purpose: ERA is considered to be a systemic disorder, but the role of local factors in driving synovial inflammation is increasingly being recognized. These joint-specific…
Abstract Number: 0401 • ACR Convergence 2023
Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index
Francesco Natalucci¹, clement triaille², Emilie Sapart², Laura BRICMAN³, Cécile VAN MULLEM², Charlotte Desmet², Stéphanie DIERCKX⁴, Marie DOYEN², Tatiana Sokolova⁵, Aleksandra AVRAMOVSKA³ and Patrick Durez², ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴CHU UCL Namur, Rheumatology, Mont-Godinne, Belgium, Mont Godinne, Belgium, ⁵Université Catholique de Louvain, Brussels, Belgium
Background/Purpose: Rheumatoid Arthritis is a chronic autoimmune disease characterized by persistent joint inflammation. According to international guidelines, the treatment target should aim to reach the…
Abstract Number: 0418 • ACR Convergence 2023
Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis
Edoardo Spolaore¹, Edward DiCarlo², Daniel Ramirez², Melanie Smith², Amit Lakhanpal², Bella Mehta³, Laura Donlin², Susan Goodman² and Dana Orange⁴, ¹HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].